

CLAIMS

1. A stable liquid anti-IL6R antibody formulation, wherein the formulation comprises a phosphate -amino acid dual buffer system.
2. The formulation according to claim 1, wherein the antibody concentration in the said formulation ranges from about 10 mg/ml to about 200 mg/ml.
3. A stable liquid formulation of anti-IL6R antibody in phosphate-amino acid dual buffer system comprising sorbitol, surfactant and optionally contains arginine and wherein, the formulation is devoid of anti-oxidant/s.
4. The formulation according to claim 3, wherein the anti-oxidant is methionine.
5. The formulation according to claim 3, wherein the antibody concentration in the formulation is about 180 mg/ml.
6. The formulation according to claim 1 or 3, wherein the antibody formulated in the phosphate-amino acid buffer remains stable under at least one of the following storage conditions such as at 2-8 °C for at least 6 months or at 25 °C for at least 6 months, or at 40 °C for at least 2 weeks, or at 40 °C for at least 4 weeks.
7. The formulation according to claim 1 or 3, wherein the formulation maintains at least 95% of monomeric content and/or contains less than 5% of aggregates of the antibody, after storage 2-8 °C for at least 6 months or at 25 °C for at least 6 months, or at 40 °C for at least 2 weeks, or at 40 °C for at least 4 weeks.
8. The formulation according to claim 1 or 3, wherein the amino acid acts as counter ion to the phosphate component of the buffer in the formulation.
9. The formulation according to claim 1 or 3, wherein the amino acid in the dual buffer system is either a histidine or glycine or aspartate or succinate.
10. The formulation according to claim 1 or 3, wherein the phosphate-amino acid dual buffer system is 'phosphate-histidine'.
11. The formulation according to claim 1 or 3, wherein the viscosity of the formulation is less than 10 cp.

12. The formulation according to claim 1 or 3, wherein the anti-IL6R antibody is tocilizumab.
13. The formulation according to claim 1 or 3, wherein the concentration of buffer and/salts in the said formulation is less than 50 mM.